CMC Blog

CM Clinics is expanding to British Columbia – CME Seats still available!!
February 17th, 2017

Hey West Coast, Canabo is hosting a CME event near you! Doctor Danial Schecter “One of Canada’s leading speakers on Medical Marijuana” and John Philpott, CEO of Canabo Medical Corp will be in the following towns on the following dates:

Kelowna – Eldorado Hotel – Feb 20th 
Abbotsford – Restaurant 62 – Feb 21st
Chilliwack – Coast Hotel – Feb 22nd 

Welcome Physicians and Nurse Practitioners, please feel free to contact Madeline Whittaker at mwhittaker@cmclinic.ca if you’d like to reserve a seat.


We look forward to seeing you as Canabo expands to Western Canada!

Canabo Medical Inc. Closes $8.4 Million Equity Financing
December 23rd, 2016

December 22, 2016 – Vancouver, BC – Canabo Medical Inc. (TSX-V: CMM) (“Canabo” or the “Company”), further to the Company’s press release dated December 7, 2016, has closed its brokered private placement with Aphria Inc. (TSX-V: APH and USOTCQB:APHQF) (“Aphria”) of 6,000,000 common shares (the “Shares”) at a price of $1.40 per share, to raise gross proceeds of $8,400,000 (the “Offering”). After giving effect to the Offering, Aphria will own approximately 16.6% of the total issued and outstanding common shares of the Company (on an undiluted basis).

The Company entered into an agreement with Haywood Securities Inc., as lead agent, PowerOne Capital Markets Limited, Clarus Securities Inc., (collectively, the “Agents”) and paid a cash commission to the Agents equal to 5% of the gross proceeds raised. The Agents have also been granted an over-allotment option to sell up to an additional 900,000 common shares at $1.40 per share. This option may be exercised at any time, in whole or in part, until January 21, 2017. The Delavaco Group also acted as a Strategic Advisor.

The Offering is subject to certain conditions including, but not limited to, the receipt of all necessary regulatory approvals, including the approval of the TSX Venture Exchange. All of the securities issued pursuant to this Offering will have a hold period expiring April 23, 2017.

Dr. Neil Smith, Executive Chairman of Canabo stated, “Aphria is a producer that aligns well with Canabo. We are both committed to advancing research to support medical cannabis treatments, and their products are achieving excellent results with many of our patients.”

About the Company – Canabo wholly owns and operates Cannabinoid Medical Clinics, or CMClinics, Canada’s largest referral-only clinics for medical cannabis. After opening in 2014, Canabo now has ten clinic locations, including Toronto, Barrie, Ottawa, Hamilton, Halifax, St. John’s, and Edmonton, with a number of additional clinics planned for opening in 2017.

The principal business carried on and intended to be carried on by Canabo is the operation of strictly referral-only medical clinics for evaluating the suitability of, prescribing, and monitoring cannabinoid treatments for patients suffering from chronic pain and disabling illnesses. Clinics operated by Canabo are staffed by physicians and qualified health care practitioners specifically trained to assess patient suitability for cannabinoid treatment, recommend treatment regimes, and monitor treatment progress. Canabo sees patients only on a physician-referral basis. The Access to Cannabis for Medical Purposes Regulations (“ACMPR”) requires that medical cannabis must be prescribed by a health care practitioner; however, no cannabinoid products or medical cannabis are sold at Canabo’s medical clinics.

For further information, please contact: 
Dr. Neil Smith, Executive Chairman
Telephone:+1-902-210-8833
Email: neilsmith@canabocorp.com
www.canabocorp.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

Forward Looking Statements

Canabo

Except for historical information, this press release contains forward-looking statements, which reflect Canabo Medical Inc.’s current expectations regarding future events. These forward-looking statements involve known and unknown risks and uncertainties that could cause Canabo’s actual results to differ materially from those statements. Those risks and uncertainties include, but are not limited to, our ability to access capital, the successful and timely completion of opening clinics, regulatory changes, competition, approvals and other business and industry risks.

The forward-looking statements in this press release are also based on a number of assumptions which may prove to be incorrect. Forward-looking statements contained in this press release represent views only as of the date of this release and are presented for the purpose of assisting potential investors in understanding Canabo’s business, and may not be appropriate for other purposes. Canabo does not undertake to update forward-looking statements, whether written or oral, that may be made from time to time by or on its behalf, except as required under applicable securities legislation. Investors are cautioned not to rely on these forward-looking statements and are encouraged to consult with a professional investment advisor.

Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

Canabo Comments on the Federal Government Task Force Report on Cannabis Legalization and Regulation
December 14th, 2016

December 14, 2016 – Vancouver, BCCanabo Medical Inc. (TSX-V: CMM) (“Canabo” or the “Company”) applauds the Federal Government Task Force Report on Cannabis Legalization and Regulation, and the need to advance research data on cannabinoid treatments.

Dr. Neil Smith, Executive Chairman of Canabo commented on the Task Force findings relating to medical access, “The Task Force Report clearly indicates the need for credible, evidence-based research.  Canabo is a global leader in advancing clinical data on cannabis treatments.”  Dr. Smith went on to say, “Canabo has already compiled a comprehensive clinical data set allowing us to identify effective cannabinoid treatments.  Our recently announced study for 2017 further demonstrates our position as the industry leader for medical data within the medical marijuana industry.”  (See Canabo news release, December 7, 2016.)

Canabo’s database of over 10,000 patients will assist in the advancement of research for the benefit of insurers, medical practitioners, clinical researchers and the pharmaceutical industry. Canabo’s dataset includes a full medical profile of each patient, cannabinoid consumption, and efficacy following the start of treatment. This data will build a long-term view of how medical marijuana is helping patients over time by condition, medication usage, and on many other fronts.

Dr. Smith points to the Company’s analysis of the effects of cannabinoid treatments on opioid use to demonstrate the importance of Canabo’s clinical data.

“A large percentage of our patient database are using opioids, including hydrocodone, oxycodone, and fentanyl for chronic pain conditions. Since Canabo tracks patient’s cannabis treatment, changes in pain levels and opioid consumption, we are equipped to respond to a variety of questions with respect to the effects of cannabis on opioid use. Do medical cannabis patients use fewer opioids over time? Do we see improvements in patient pain levels, overall health and quality of life?  Is medical cannabis more impactful with certain medical conditions?  What cannabis strains and dosage levels have the greatest impact on specific conditions?

Almost three-quarters of patients had been coping with their medical ailment in excess of three years before coming to Canabo. Our patient data is characterized by long-term, persistently chronic ailments. This suggests that patient improvements following cannabinoid treatments are not just a function of recovery over time, and that our dataset is crucial to understanding the interaction of cannabis with patient health.”

Dr. Smith congratulates the Federal Task Force for its insight relating to the requirement for evidence- based research relating to cannabis treatments.

About the Company

Canabo wholly owns and operates Cannabinoid Medical Clinics, or CMClinics, Canada’s largest physician led referral-only clinics for medical cannabis. Established in 2014, Canabo has ten clinics located in Toronto, Barrie, Ottawa, Hamilton, Halifax, St. John’s, Calgary and Edmonton, with a number of additional clinics planned for opening in 2016 and 2017.

Canabo operates referral-only medical clinics dedicated to evaluating the suitability of prescribing, and monitoring cannabinoid treatments for patients suffering from chronic pain and disabling illnesses. Clinics operated by Canabo are staffed by physicians and qualified health care practitioners specifically trained to assess patient suitability for cannabinoid treatment, recommend treatment regimes, and monitor treatment progress.

For further information, please contact:

Dr. Neil Smith, Executive Chairman

Telephone: +1-902-210-8833
Email: neilsmith@canabocorp.com

www.canabocorp.com

Forward Looking Statements

Except for historical information, this press release contains forward-looking statements, which reflect Canabo Medical Inc.’s current expectations regarding future events. These forward-looking statements involve known and unknown risks and uncertainties that could cause Canabo’s actual results to differ materially from those statements. Those risks and uncertainties include, but are not limited to, our ability to access capital, the successful and timely completion of opening clinics, regulatory changes, competition, approvals and other business and industry risks.

The forward-looking statements in this press release are also based on a number of assumptions which may prove to be incorrect. Forward-looking statements contained in this press release represent views only as of the date of this release and are presented for the purpose of assisting potential investors in understanding Canabo’s business, and may not be appropriate for other purposes. Canabo does not undertake to update forward-looking statements, whether written or oral, that may be made from time to time by or on its behalf, except as required under applicable securities legislation. Investors are cautioned not to rely on these forward-looking statements and are encouraged to consult with a professional investment advisor.

7,500 Patient Observational Study, and $8.4 Million Equity Financing
December 8th, 2016

December 7, 2016 – Vancouver, BC – Canabo Medical Inc. (TSX-V: CMM) (“Canabo” or the “Company”) today announces its intention to complete a 7,500 patient observational study in 2017.  The study will be led by Andrew Davis, Ph.D., of Acadia University, and will focus on correlations within the patient database in three specific areas;

  • relation of opioid use following cannabinoid therapies by condition and patient category
  • relation of benzodiazepines use following cannabinoid therapies by condition and patient category, and
  • change in quality of life measurements following cannabinoid therapies by condition and patient category.

The study will complete participant enrollment in 2017, is expected to publish initial results in late 2017, and complete study findings in 2018.    

Canabo is also pleased to announce it has entered into an agreement with Aphria Inc. (TSX-V: APH and USOTCQB:APHQF) (“Aphria”) for the private placement of 6,000,000 common shares (the “Shares”) at a price of $1.40 per Share, to raise gross proceeds of $8,400,000 (the “Offering”).  After giving effect to the Offering, Aphria will own approximately 16.6% of the total issued and outstanding common shares of the Company (on an undiluted basis).  The placement will be subject to an aggregate finders’ fee equal to 5% of the gross proceeds payable to Haywood Securities Inc., PowerOne Capital Markets Limited and Clarus Securities Inc.  In addition, Haywood Securities Inc. shall be granted an over-allotment option to sell additional common shares equal to 15% of the size of the offering.  This option may be exercised at any time, in whole or in part, until 30 days following the closing date.

The Offering is subject to certain conditions including, but not limited to, the receipt of all necessary regulatory approvals, including the approval of the TSX Venture Exchange.  All of the securities issued pursuant to this Offering will have a hold period expiring four months after the closing date.

Dr. Neil Smith, Executive Chairman of Canabo Medical stated, “The study announcement speaks to the core principles and values of Canabo, contributing to the evidence based medical body of work to support cannabinoid therapies.”  Smith went on to say, “Adding an investment partner like Aphria is an obvious strategic partner aligned to advance the standard of cannabinoid treatments.”

“Canabo is one of the largest and most respected referral clinics in the country. It’s commitment to educating both patients and physicians when it comes to prescribing cannabinoid treatment to effectively manage patients suffering from chronic pain and disabling illnesses, has resulted in Canabo becoming a market leader in cannabinoid medicine and assuring it is playing a meaningful role in improving the quality of life of their patients, consistent with the values we hold at Aphria,” said Vic Neufeld, Chief Executive Officer of Aphria Inc. “We very much look forward to working closely with them as part of this strategic investment.”

About Canabo  

Canabo wholly owns and operates Cannabinoid Medical Clinics, or CMClinics, Canada’s largest referral-only clinics for medical cannabis. After opening in 2014, Canabo now has ten clinic locations, including Toronto, Barrie, Ottawa, Hamilton, Halifax, St. John’s, and Edmonton, with a number of additional clinics planned for opening in 2016 and 2017.

The principal business carried on and intended to be carried on by Canabo is the operation of strictly referral-only medical clinics for evaluating the suitability of, prescribing, and monitoring cannabinoid treatments for patients suffering from chronic pain and disabling illnesses. Clinics operated by Canabo are staffed by physicians and qualified health care practitioners specifically trained to assess patient suitability for cannabinoid treatment, recommend treatment regimes, and monitor treatment progress. Canabo sees patients only on a physician-referral basis. The Access to Cannabis for Medical Purposes Regulations (“ACMPR”) requires that medical marijuana must be prescribed by a health care practitioner; however, no cannabinoid products or medical marijuana are sold at Canabo’s medical clinics.  

For further information, please contact:

Dr. Neil Smith, Executive Chairman  

Telephone: +1-902-210-8833 Email: neilsmith@canabocorp.com www.canabocorp.com

About Aphria

Aphria Inc., one of Canada’s lowest cost producers, produces, supplies and sells medical cannabis.  Located in Leamington, Ontario, the greenhouse capital of Canada.  Aphria is truly powered by sunlight, allowing for the most natural growing conditions available.  We are committed to providing pharma-grade medical cannabis, superior patient care while balancing patient economics and returns to shareholders.  We are the first public licenced producer to report positive cash flow from operations and the first to report positive earnings in consecutive quarters.  

For further information, please contact:   

Vic Neufeld

President & CEO

1-844-427-4742

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.  

Forward Looking Statements

Canabo

Except for historical information, this press release contains forward-looking statements, which reflect Canabo Medical Inc.’s current expectations regarding future events. These forward-looking statements involve known and unknown risks and uncertainties that could cause Canabo’s actual results to differ materially from those statements. Those risks and uncertainties include, but are not limited to, our ability to access capital, the successful and timely completion of opening clinics, regulatory changes, competition, approvals and other business and industry risks.  

The forward-looking statements in this press release are also based on a number of assumptions which may prove to be incorrect. Forward-looking statements contained in this press release represent views only as of the date of this release and are presented for the purpose of assisting potential investors in understanding Canabo’s business, and may not be appropriate for other purposes. Canabo does not undertake to update forward-looking statements, whether written or oral, that may be made from time to time by or on its behalf, except as required under applicable securities legislation. Investors are cautioned not to rely on these forwardlooking statements and are encouraged to consult with a professional investment advisor.

Aphria

Certain information in this news release constitutes forward-looking statements under applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as “may”, “should”, “anticipate”, “expect”, “believe”, “intend” or the negative of these terms and similar expressions. Forward-looking statements in this news release include, but are not limited to, statements with respect to internal expectations, investment in Canabo.  Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; future legislative and regulatory developments involving medical marijuana; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the medical marijuana industry in Canada generally, income tax and regulatory matters; the ability of Aphria to implement its business strategies; competition; crop failure; currency and interest rate fluctuations and other risks.  

Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

Canabo Announces an up to 20,000 Patient Operating Agreement in Alberta
December 6th, 2016

Canabo Announces an up to 20,000 Patient Operating Agreement in Alberta

December 5, 2016 – Vancouver, BC – Canabo Medical Inc. (TSX-V: CMM) (“Canabo” or the “Company”) today announces it has entered into a letter of intent (“LOI”) with Peak Pulmonary Consulting Inc. (“Peak Medical Group”) incorporated under the laws of Alberta.  Peak Medical Group will provide medical marijuana treatments and therapies within the Pinnacle Medical Centers through a wholly owned subsidiary, CieloMed.  Pinnacle Medical Centers currently provide medical services to over 55,000 patients in Alberta.

Under the terms of the agreement, Peak Medical Group will provide physicians and clinic space to assess up to 20,000 new patients under Canabo medical marijuana assessment, prescribing, educational procedures and protocols.  Training for up to 60 Peak Medical Group physicians and educators in Canabo’s proprietary training protocols will begin immediately. All resulting patients under this agreement will also be enrolled in Canabo’s medical data collection program.

Operational services will be provided by Peak Medical Group under the terms of a share exchange agreement (“SEA”) with Canabo.   Under the terms of the SEA, Canabo will acquire all the issued and outstanding shares of CieloMed on the earlier of: CieloMed assessing a minimum of 20,000 patients under Canabo’s medical marijuana protocols; or six years from the date of the SEA.  At closing, based on a 8-day VWAP for the period immediately preceding the execution of the LOI, Canabo will issue up to approximately 1,928,000 common shares (up to 6.4% of the issued and outstanding shares of Canabo), representing up to a maximum deemed value of $1,600,000 in Canabo shares.  Any shares issued under the SEA will be subject to a 12-month voluntary pooling agreement.  The agreement is subject to both parties maintaining certain performance and quality assurance provisions, the execution of the SEA and TSX Venture Exchange approval.

Dr. Neil Smith, Executive Chairman of Canabo stated, “This agreement represents a significant accelerant to our previous clinic roll out schedule.  Pinnacle has the ability to provide Canabo patient care in up to 20 new locations in 2017.”  Dr. Smith indicated that the cornerstone of this agreement is a likeminded commitment to the highest standards of patient care, “I have known the operators of Pinnacle Medical Centers for several years now; their physician approach is just like ours, physicians dedicated to providing the highest standard of care.  We all believe medical marijuana represent serious medication for real conditions, and that specially trained physicians are in the best position to work with patients’ existing treatments.”

Shawn Nicol, President of Peak Medical Group added, “We expect to begin offering Canabo treatment protocols in up to 3 or 4 of our clinic locations by January.  We expect to expand services to the majority of Peak Medical Group locations during the first half of 2017.”

About the Company

Canabo Medical Inc. is a Canadian corporation incorporated on March 19, 2014. Canabo wholly owns and operates Cannabinoid Medical Clinics, Canada’s largest referral-only clinics for medical cannabis. After opening in 2014, Canabo now has ten clinic locations, including Toronto, Barrie, Ottawa, Hamilton, Halifax, St. John’s, and Edmonton, with a number of additional clinics planned for opening in 2016 and 2017.

The principal business carried on and intended to be carried on by Canabo is the operation of strictly referral-only medical clinics for evaluating the suitability of, prescribing, and monitoring cannabinoid treatments for patients suffering from chronic pain and disabling illnesses. Clinics operated by Canabo are staffed by physicians and qualified health care practitioners specifically trained to assess patient suitability for cannabinoid treatment, recommend treatment regimes, and monitor treatment progress. Canabo sees patients only on a physician-referral basis. The Access to Cannabis for Medical Purposes Regulations (“ACMPR”) requires that medical marijuana must be prescribed by a health care practitioner; however, no cannabinoid products or medical marijuana are sold at Canabo’s cannabinoid medical clinics.

For further information, please contact:

Dr. Neil Smith, Executive Chairman

Telephone: +1-902-210-8833
Email: neilsmith@canabocorp.com

www.canabocorp.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

Forward Looking Statements

Except for historical information, this press release contains forward-looking statements, which reflect Canabo Medical Inc.’s current expectations regarding future events. These forward-looking statements involve known and unknown risks and uncertainties that could cause Canabo’s actual results to differ materially from those statements. Those risks and uncertainties include, but are not limited to, our ability to access capital, the successful and timely completion of opening clinics, regulatory changes, competition, approvals and other business and industry risks.

The forward-looking statements in this press release are also based on a number of assumptions which may prove to be incorrect. Forward-looking statements contained in this press release represent views only as of the date of this release and are presented for the purpose of assisting potential investors in understanding Canabo’s business, and may not be appropriate for other purposes. Canabo does not undertake to update forward-looking statements, whether written or oral, that may be made from time to time by or on its behalf, except as required under applicable securities legislation. Investors are cautioned not to rely on these forward-looking statements and are encouraged to consult with a professional investment advisor.

Contact Us

Phone: 1-888-282-7763
Fax: 1-844-320-9652

Our Patient Care Centre is open Monday through Friday from 7:30am to 7:00pm (EST) 

 

Ontario: 

Barrie, ON 
11 Lakeside Terrace, 2nd Floor

Bracebridge, ON
345 Ecclestone Drive

Burlington, ON
2951 Walkers Line, 3rd Floor, Suite 305  

Hamilton, ON
414 Victoria Ave., Suite M8  

Kingston, ON 
725 Arlington Park Place  

London, ON
130 Thompson Road 

Ottawa, ON  
1385 Bank St., Suite 305

St Catharines, ON 
Niagara Health Center, 180 Vine Street South, Suite 104

Stoney Creek, ON
35 Upper Centennial Pkwy., 2nd Floor  

Toronto, ON 
1 Eglinton Ave. E., Suite 407

Atlantic: 

Sackville, NB
112 Main Street, Unit D

St. John’s, NL
8-10 Rowan St., Suite 206

Halifax, NS 
5991 Spring Garden Rd., Suite 440

Wolfville, NS
2 – 4 Little Road


Western: 

Edmonton, AB
11010-101 St. NW, Suite 608

Calgary, AB
70 Country Hills Landing NW, Suite 103   

Chilliwack, BC
9181 Main Street, Suite 214  

Kelowna, BC
3975 Lakeshore Road, Suite 302